CN102917694A - 依泽替米贝的片剂制剂 - Google Patents

依泽替米贝的片剂制剂 Download PDF

Info

Publication number
CN102917694A
CN102917694A CN2011800272195A CN201180027219A CN102917694A CN 102917694 A CN102917694 A CN 102917694A CN 2011800272195 A CN2011800272195 A CN 2011800272195A CN 201180027219 A CN201180027219 A CN 201180027219A CN 102917694 A CN102917694 A CN 102917694A
Authority
CN
China
Prior art keywords
tablet
ezetimibe
hydrochloride
weight
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800272195A
Other languages
English (en)
Chinese (zh)
Inventor
罗伯特·T·卢姆
斯特凡·D·帕伦特
乔春生
史蒂文·R·修
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telik Inc
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc filed Critical Telik Inc
Publication of CN102917694A publication Critical patent/CN102917694A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2011800272195A 2010-06-07 2011-03-29 依泽替米贝的片剂制剂 Pending CN102917694A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35237710P 2010-06-07 2010-06-07
US61/352,377 2010-06-07
PCT/US2011/030376 WO2011156045A2 (en) 2010-06-07 2011-03-29 Tablet formulation of ezatiostat

Publications (1)

Publication Number Publication Date
CN102917694A true CN102917694A (zh) 2013-02-06

Family

ID=42829329

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800272195A Pending CN102917694A (zh) 2010-06-07 2011-03-29 依泽替米贝的片剂制剂

Country Status (8)

Country Link
US (2) US20110300215A1 (https=)
EP (1) EP2576591A2 (https=)
JP (1) JP2013528213A (https=)
CN (1) CN102917694A (https=)
AR (1) AR080895A1 (https=)
CA (1) CA2797458A1 (https=)
TW (1) TW201143761A (https=)
WO (1) WO2011156045A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012151051A1 (en) * 2011-05-03 2012-11-08 Telik, Inc. Excipient compatibility with ezatiostat
US20130035389A1 (en) 2011-08-05 2013-02-07 Telik, Inc. Methods for treating myelodysplastic syndrome with ezatiostat
US10156885B2 (en) 2014-04-07 2018-12-18 Avago Technologies International Sales Pte. Limited Network energy consumption reduction
US11804732B2 (en) 2015-01-20 2023-10-31 Ge Hybrid Technologies, Llc Wireless power transmission device, and transmission power control method therefor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1520283A (zh) * 2001-04-26 2004-08-11 ����˹�ж�-����˹˹������˾ 通过结晶作用控制的压紧性
CN101133020A (zh) * 2004-12-03 2008-02-27 特瓦制药工业有限公司 依泽替米贝多晶型
CN101679236A (zh) * 2007-01-24 2010-03-24 克尔克公司 依泽替米贝的制备方法和其的衍生物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599903A (en) 1992-04-03 1997-02-04 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
US5114003A (en) * 1991-03-28 1992-05-19 E. I. Du Pont De Nemours And Company Tablet vial with desiccant in bottom
US5786336A (en) 1991-04-29 1998-07-28 Terrapin Technologies, Inc. Target-selective protocols based on mimics
US5955432A (en) * 1992-04-03 1999-09-21 Terrapin Technologies, Inc. Metabolic effects of certain glutathione analogs
US5965164A (en) 1994-10-28 1999-10-12 Fuisz Technologies Ltd. Recipient-dosage delivery system
TW576838B (en) * 1998-04-16 2004-02-21 Teijin Ltd Glutathione derivatives and application form thereof
US7029695B2 (en) 2001-07-10 2006-04-18 Telik, Inc. Therapeutic compositions containing glutathione analogs
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2005065639A2 (en) 2003-11-21 2005-07-21 Torrent Pharmaceuticals Limited Novel pharmaceutical compositions
BRPI0606520A2 (pt) * 2005-01-06 2009-06-30 Telik Inc tripeptìdeo e tetrapeptìdeo tioéteres
DE602006012962D1 (de) 2006-07-19 2010-04-29 Tabuk Pharmaceutical Mfg Co Pharmazeutische Zubereitungen von Ciprofloxacin
EP2114380A1 (en) 2007-01-25 2009-11-11 Panacea Biotec Ltd. Modified release pharmaceutical composition and a process of making the same
MX2010001711A (es) 2007-08-13 2010-03-11 Panacea Biotec Ltd Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas.
AR068745A1 (es) 2007-10-08 2009-12-02 Panacea Biotec Ltd Una composicion en forma de dosificacion farmaceutica oral de unidad de alta dosis de micofenolato sodico, metodo para utilizar dicha composicion y sus usos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1520283A (zh) * 2001-04-26 2004-08-11 ����˹�ж�-����˹˹������˾ 通过结晶作用控制的压紧性
CN101133020A (zh) * 2004-12-03 2008-02-27 特瓦制药工业有限公司 依泽替米贝多晶型
CN101679236A (zh) * 2007-01-24 2010-03-24 克尔克公司 依泽替米贝的制备方法和其的衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AZRA RAZA ET AL: ""Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome"", 《BLOOD》 *

Also Published As

Publication number Publication date
JP2013528213A (ja) 2013-07-08
US8361971B2 (en) 2013-01-29
US20120021054A1 (en) 2012-01-26
EP2576591A2 (en) 2013-04-10
TW201143761A (en) 2011-12-16
US20110300215A1 (en) 2011-12-08
WO2011156045A2 (en) 2011-12-15
WO2011156045A3 (en) 2012-05-31
CA2797458A1 (en) 2011-12-15
AR080895A1 (es) 2012-05-16

Similar Documents

Publication Publication Date Title
JP6028016B2 (ja) リナグリプチンベンゾエートの多形体
EP3565542B1 (en) Polymorphic forms of rad1901-2hcl
JP6034789B2 (ja) 結晶性ナロキソール−ｐｅｇ接合体
TW200944508A (en) Novel solid forms of bendamustine hydrochloride
AU2019297421B2 (en) Polymorphic forms of RAD 1901-2HCL
WO2023186834A1 (en) Crystalline hydrobromide salt of 5-meo-dmt
KR102447769B1 (ko) 발베나진 토실산염의 결정형 및 그 제조 방법 및 용도
WO2005023198A2 (en) Modafinil compositions
CN102917694A (zh) 依泽替米贝的片剂制剂
CN103025753A (zh) 晶体盐酸依泽替米贝非溶剂化物
EP1755388A1 (en) Mixed co-crystals and pharmaceutical compositions comprising the same
US20220298158A1 (en) Polymorph of venetoclax and method for preparing the polymorph
EP1670753A2 (en) Modafinil compositions
WO2018130226A1 (zh) 利奥西呱的新晶型及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130206